Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co spinoff Organon launches with the aim of 'improving health outcomes for women'

Merck & Co – known as MSD outside the US and Canada – announced its plans for the women’s health spinoff company last month

Merck & Co spinoff company Organon has launched with the aim of making ‘a better and healthier every day for every woman’.

Merck & Co – known as MSD outside the US and Canada – announced its plans for the women’s health spinoff company last month.

Organon’s portfolio contains over 60 medicines and products across three core franchises at launch – women’s health, biosimilars and established brands.

In Merck & Co's 2020 sales, products within Organon’s roster brought in approximately $6.6bn, with many of those sales driven by its contraceptive and biosimilars franchises.

In particular, much of Organon’s growth prospects exist outside the US, with nearly 80% of the revenue generated by its products coming from international markets.

“The spinoff of Organon will help Merck become a leaner, more focused and agile company with stronger growth, and will enable significant operating efficiencies,” said Rob Davis, president, Merck & Co.

Organon is planning to go beyond offering products for contraception and fertility in a bid to ‘broaden its definition of women’s health’, to address conditions that either are unique to women or that disproportionately affect them.

The new spinoff company has also launched with a majority-female leadership team – the company will be headquartered in the US but has additional offices across the globe, including in Shoreditch, London.

To coincide with the launch, Organon created a multimedia installation – known as the ‘Wall of Voices’ – outside the New York Stock Exchange in the US.

The installation showcases perspectives, voices and images of women highlighting the health issues that are important to them, Organon said in a statement.

“It’s exciting to take the helm in a new and vibrant company with such a strong purpose; a commitment to improving health outcomes for women,” said Simon Nicholson, managing director of Organon UK&ENI Cluster.

“New acquisitions and partnerships will help Organon expand beyond our core strengths in contraceptives and fertility to meet the health needs of women at all stages of her life. This will be fuelled by a refreshed focus on our women’s health portfolio, further biosimilar launches, and a renewed energy put behind our trusted dermatology, pain, respiratory and cardiovascular brands,” he added.

Article by
Lucy Parsons

3rd June 2021

From: Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...